DKSH has signed a distribution agreement with TdB Labs, a leading Swedish biotech company specializing in developing and manufacturing dextran derivatives and other polysaccharides, for India. Through its distribution network and service offering, DKSH will boost business opportunities for the partnership in this key market.
Mumbai, India, April 23, 2024 – DKSH’s Business Unit Performance Materials, a leading distributor of specialty chemicals and ingredients, will provide business development, marketing, sales, logistics, and distribution services for TdB Labs’ range of dextran derivatives and other polysaccharides for pharmaceutical companies and diagnostic laboratories in India.
TdB Labs’ product portfolio consists of dextran derivatives, fluorescent and non-fluorescent polysaccharide derivatives, as well as derivatives of other polysaccharides such as polysucrose, inulin, hyaluronic acid, trehalose, and hydroxyethyl starch. The application areas range from studies of permeability, drug delivery, biomaterials, and colitis to applications in the processing of clinical products. TdB Labs’ polysaccharide derivatives are also used in diagnostic kits and as molecular markers while the dextran sulfates are used as an anticlumping agent for cell media.
TdB Labs has entrusted DKSH to grow its pharmaceutical business in India. This is thanks to DKSH’s extensive distribution network, highly specialized commercial and technical teams, and strong capabilities in logistics and value-added services, including technical and regulatory support.
Charlotte de Belder Tesséus, CEO, TdB Labs AB, commented: “The expertise and market presence of DKSH in India provides us with a unique opportunity to meet the growing demand for polysaccharides in the region. Our team is excited about the possibilities this partnership will open up and is committed to delivering high-quality products and services to our new customers. I am confident that together with DKSH, we will achieve remarkable success and create lasting value for our stakeholders.”
Vishal Jawale, Managing Director and Country Management Head, DKSH India, commented: “We are thrilled to partner with TdB Labs and bring their range of dextran derivatives and other polysaccharides for the pharmaceutical industry to India. TdB Labs’ dextran and other polysaccharide derivatives are highly biocompatible and widely employed within life science. We are confident that our use of traditional and digital distribution and marketing channels will deliver exceptional results.”
About TdB Labs
TdB Labs AB is a Swedish biotech company specialized in manufacturing dextrans and its various fluorescent and non-fluorescent derivatives. We have more than 50 years’ experience of working with polysaccharides. Our catalogue contains an extensive list of products that are all animal origin free and they possess a variety of life science applications. We have wide customer outreach as we currently supply these products to more than 55 countries globally. We even have the capacity to manufacture products as per the customers’ requirements along with having an analytical platform. You can read more about our company and products here: www.tdblabs.se
About DKSH
DKSH’s purpose is to enrich people’s lives. For almost 160 years, DKSH has been delivering growth for companies in Asia and beyond across its Business Units Healthcare, Consumer Goods, Performance Materials, and Technology. As a leading Market Expansion Services provider, DKSH offers sourcing, market insights, marketing and sales, eCommerce, distribution and logistics as well as after-sales services. DKSH is a participant of the United Nations Global Compact and adheres to its principles-based approach to responsible business. Listed on the SIX Swiss Exchange, DKSH operates in 36 markets with 29,040 specialists, generating net sales of CHF 11.1 billion in 2023. DKSH Business Unit Performance Materials distributes specialty chemicals and ingredients for food, pharmaceutical, personal care, and various industrial applications. With 53 innovation centers and regulatory support worldwide, DKSH creates cutting-edge formulations that comply with local regulations. With around 1,600 specialists, the Business Unit generated net sales of CHF 1.4 billion in 2023. www.dksh.com/pm